Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Kinase Inhibitor [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
PALBOCICLIB 91,024 11,066 12.2% 13,442 870 66.0 yrs 97.7%
IBRUTINIB 75,087 12,580 16.8% 24,920 1,697 71.2 yrs 39.2%
RUXOLITINIB 68,133 10,908 16.0% 14,461 1,288 59.7 yrs 48.8%
IMATINIB 43,161 13,761 31.9% 7,264 1,050 55.7 yrs 47.2%
EVEROLIMUS 39,640 8,374 21.1% 11,211 1,311 53.4 yrs 60.0%
CABOZANTINIB S-MALATE 39,270 4,203 10.7% 6,193 423 65.0 yrs 29.9%
LENVATINIB 33,766 4,449 13.2% 19,975 1,326 65.4 yrs 55.8%
DASATINIB 30,019 2,681 8.9% 6,437 669 56.4 yrs 51.9%
RIBOCICLIB 27,997 4,501 16.1% 6,700 1,220 60.2 yrs 99.0%
OSIMERTINIB 27,750 12,456 44.9% 5,277 757 68.2 yrs 66.0%

Head-to-Head Comparisons

PALBOCICLIB vs IBRUTINIB PALBOCICLIB vs RUXOLITINIB PALBOCICLIB vs IMATINIB PALBOCICLIB vs EVEROLIMUS IBRUTINIB vs RUXOLITINIB IBRUTINIB vs IMATINIB IBRUTINIB vs EVEROLIMUS RUXOLITINIB vs IMATINIB RUXOLITINIB vs EVEROLIMUS IMATINIB vs EVEROLIMUS
← Back to Kinase Inhibitor [EPC] Class side effects →